Advertisement
Advertisement
U.S. Markets close in 4 hrs 54 mins
Advertisement
Advertisement
Advertisement
Advertisement

Genfit S.A. (GNFT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.9600-0.0100 (-0.25%)
As of 10:59AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.9700
Open3.9600
Bid3.9200 x 1200
Ask3.9700 x 1200
Day's Range3.9399 - 3.9700
52 Week Range3.0200 - 5.0500
Volume2,231
Avg. Volume8,108
Market Cap197.269M
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-3.1400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    GENFIT Announces Revenues and Cash Position as of December 31, 2022

    Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022. Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); February 28, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its cash position as of December 31, 2022 and revenues for 2022. 1 2 Financials As of December 3

  • InvestorPlace

    The 7 Best Biotech Stocks to Buy for February 2023

    While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy. By that, I mean biotechnology firms may enjoy some economic insulation as their relevance supersedes variables like interest rate dynamics. Still, it doesn’t mean that the best biotech stocks to buy are immune from

  • GlobeNewswire

    GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 30, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the

Advertisement
Advertisement